136 related articles for article (PubMed ID: 29117640)
1. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro.
Li YH; Lin QM; Pang NH; Zhang XD; Huang HL; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):337-344. PubMed ID: 31058459
[TBL] [Abstract][Full Text] [Related]
3. Functional assessment of
Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX
Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro.
Li YH; Lu XR; Lin QM; Huang HL; Liang XL; Cai JP; Cui J; Hu GX
J Pharm Pharmacol; 2019 Nov; 71(11):1677-1683. PubMed ID: 31441067
[TBL] [Abstract][Full Text] [Related]
5. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX
Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro.
Cai Y; Lin Q; Jin Z; Xia F; Ye Y; Xia Y; Papadimos TJ; Wang Q; Hu G; Cai J; Chen L
Chem Res Toxicol; 2021 Jan; 34(1):103-109. PubMed ID: 33393779
[TBL] [Abstract][Full Text] [Related]
7. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.
Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J
Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813
[TBL] [Abstract][Full Text] [Related]
8. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.
Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G
Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224
[TBL] [Abstract][Full Text] [Related]
9. Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism.
Chen B; Zhang XD; Wen J; Zhang B; Chen D; Wang S; Cai JP; Hu GX
Chem Res Toxicol; 2020 Jan; 33(1):172-180. PubMed ID: 31560202
[TBL] [Abstract][Full Text] [Related]
10. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
[TBL] [Abstract][Full Text] [Related]
11. Possible influence of some foods on the metabolism of ibrutinib.
Kronabel D
Clin Lab; 2015; 61(3-4):443-4. PubMed ID: 25975016
[TBL] [Abstract][Full Text] [Related]
12. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
13. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
14. Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro.
Xie SL; Zhu X; Gao N; Lin Q; Chen C; Yang YJ; Cai JP; Hu GX; Xu RA
Food Chem Toxicol; 2023 Nov; 181():114101. PubMed ID: 37863381
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro.
Yang CC; Zheng X; Liu TH; Wang CC; Tang PF; Chen Z; Zhang BW; Fang P; Hu GX; Cai JP
Xenobiotica; 2019 Jan; 49(1):120-126. PubMed ID: 29394111
[TBL] [Abstract][Full Text] [Related]
16. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
Miyazaki M; Nakamura K; Fujita Y; Guengerich FP; Horiuchi R; Yamamoto K
Drug Metab Dispos; 2008 Nov; 36(11):2287-91. PubMed ID: 18669585
[TBL] [Abstract][Full Text] [Related]
17. Functional gene variants of CYP3A4.
Werk AN; Cascorbi I
Clin Pharmacol Ther; 2014 Sep; 96(3):340-8. PubMed ID: 24926778
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
Akiyoshi T; Saito T; Murase S; Miyazaki M; Murayama N; Yamazaki H; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Dispos; 2011 Apr; 39(4):724-8. PubMed ID: 21212239
[TBL] [Abstract][Full Text] [Related]
19. Identification and Functional Assessment of Eight
Qi Y; Yang H; Wang S; Zou L; Zhao F; Zhang Q; Hong Y; Luo Q; Zhou Q; Geng P; Chen H; Ji F; Cai J; Dai D
Drug Metab Dispos; 2024 Feb; 52(3):218-227. PubMed ID: 38195522
[TBL] [Abstract][Full Text] [Related]
20. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Brandes LJ; Queen GM; LaBella FS
Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
